Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2.) It was pre-planned … and I am sure he has a reason … he need the money
3.) He sold app. 600k shares … less than 10% of his shares
Options players that exited their position probably are going WTF!
Impressive movement the pro's are buying hand over fist!
I could make one more argument - the ADCOM panel had no knowledge of the biological benefits of EPA.
Please only an idiot would exercise options and sell with an eminent buyout.
Well it pulled back to my selling price buckoo. Let's see how the day ends. I'll buy back - will the marketeers knock it down a little more today? I will be ready for ACC meeting, I will buy even if it is up slightly - holding all you shares is boring. Nice to have some trading shares to add to the fun! It's worked out well a couple of times already.
Many people thought it was a sure thing going into the first ADCOM including Amarin participants. There will be plenty of nervous investors.
It really depends on the panel members that the FDA tosses in the mix and the MO argument once again. At least they will be prepared for this argument.
I still don't understand why patients still buy gL or L.
And as mention. much, much easier to search for specific items by index or even running a search on a electronic document. The paperless system should help speed up the process. Storage it is much safer.
A funny example: I was married 'first marriage' in Florida and divorced on island about 20 years ago before remarrying. So I called the family court here on island and I gave her some info over the phone. She said she could not find the file in the system, of coarse, come to the court, so I went, I found the lawyers filings before I left, so I had a date. So after looking a few minutes she said she found it, It's sitting in a nearly condemned warehouse, but it will take about three weeks to get it.
She said it was damaged by the Hurricane and some of the shelves are tipped over so we have to send some one to find it. So I said not problem just give me the divorce date, that's all I need for now and let me know when you have a divorce decree for me. So hopefully she calls me in 3 weeks.
So electronic filing will always be safer as long as you have backup and easier to find what your looking for.
N40K, looks like marketeers could play with options players tomorrow. Bring it below $20 that it is. You just never know.
Trade Details 1,624 231 -0.76 1.54 1.35 1.76 19.00 0.06 0.10 0.05 -0.10 58 965 Details Trade
Trade Details 1,954 38 -0.60 1.10 0.95 1.14 19.50 0.06 0.20 0.05 -0.14 21 491 Details Trade
Trade Details 4,182 450 -0.74 0.69 0.60 0.75 20.00
I think this was expected after earnings, just a delayed effect maybe. Possible I can buy back my trading shares if it dips further by Friday. Maybe marketeers will try and take out some options players.
Are you invested in ACAD? I was, but put money back in Amarin. I kind wish I kept it there, PPS has really climbed. Baker Brothers invested/added to their position I believe 20 million recently. I think Amarin has more potential and less risk.
J.T. not stupid if he was seriously considering selling the company he would not have sold his options he exercised. I mean what kind of fool would do that?
CNBC Follow up article:
CNBC-JT-AMRN
Actually the thread contained both BOTZ which was a comparison with 100% of fund money invested in various types stock. I can't past graphs here. The portfolio report looked right on. So to prove LABU portfolio report was wrong. I would need proof from you, not just an opinion. Like a portfolio report for LABU from another site.
If you are suggesting this as a dividend stock to volatile for me and the Dividend Yield 3.69% looks low compared to AGNC which has been vary stable with a div payment of .18/12.31% (per month). CHL looks like it's doing very well with room to run hoping the market settles down I may buy some if it drops a bit.
Amarin had very high volume yesterday, all because of rev's?
Unexpected I was not happy with earnings, I would have sold my trading shares yesterday rather than the day before CC. That's OK I bought some AGNC shares and if the AMRN price settles down, I will buy back but need's to drop to 19 to make it worth wild. Hopefully the PPS settles at 21 or so, I have to pay taxes, but I still have some time, a month and a half to make a little more money for taxes with shares I may purchase.
Yes the Fad's have gotten pretty good at expanding their paperless systems. Which is a good thing less paper waste.
I'm not rooting for down - I would not my if it takes a dip though!
I can continue to build my share count. I still deposit money bi monthly from my salary for investments so I'd rather buy AMRN at the cheaper prices. I will eventually sell AMRN for dividend paying stocks which I have fair amount of currently.
This stock will not settle down for some time, so taking some chances.
We can only hope.
Looks like it did not hold, lets see what happens before the close and tomorrow.
Run a large trial based on high AA/EPA ratios 5 or 6 years low to medium risk patients not based on lipid levels. Remember half the victims of heart attacks that end up in emergency room's don't have high levels of LDL-C or out of wack lipids. I think the current information show's greater than 60% ER visits have normal lipid levels.
Wheres your proof? BOTZ seemed correct.
Not necessarily, it's a rumor, not an announcement.
Just what I was thinking - there is some underlying strength and it was not the earnings. Maybe revenues was enough, but not usually.
That for sure - $40-$50 is out of the question.
Actually I did not sell the complete set of trading shares, sold around 2300 shares. Not really the day is young and made some nice profit. A small portion goes to the tax man. Even though we have for kids, I have to pay ~7,000. This stock will remain volatile for awhile. Although with mixed earnings I'm surprised the marketeers brought it up. No problem if it stays up.
$40 no way...
I wish they would test Vascepa as single agent, rather than an add on to other drugs. Nip CVD in the butt, tackle it in it's early stages or before disease set's in, as a preventative medicine which may have positive effects in reducing cancer and chronic disease.
Something we investors new all along, thanks to J.L.'s medical knowledge, which seems to be vast compared to some of his peers and our combined research.
As predicted.. I believe the stock heads south Today. Revenues don't mean much if spending defeats the income. These type of mixed reports will lead to a short decline in PPS. So anyone trading shares should have sold around $20.40 yesterday and buy in a couple of days!
5:19 AM ET Amarin misses by $0.03, beats on revs; reaffirms FY19 revs guidanceBriefing.com
5:02 AM ET Amarin 4Q Loss/Shr 11c >AMRNDow Jones
Net product revenue for the years ended December 31, 2018 and 2017 was $228.4 million..
Selling, general and administrative expenses for the years ended December 31, 2018 and 2017 were $227.0 million.
So hopefully revenue starts accelerating and spending slows down.
Nothing wrong with good timing. I considered myself lucky yo buy OPI and BOTZ at the low point. I sold OPI at near its high of ~33 was(GOV) but kept BOTZ.
Of course that will change with the sNDA, you will still have off label scripts, but the percentage will not be like it is now. Scripts show up in the system off label or not at the retail level.
I mention it, I have Etrade portfolio information on Funds,ETF's etc. Portfolio TAB and others are available after you load the desired stock symbol which is the trading sceen, displays the investments and percentages stock/bonds/cash etc.
Well be careful dont't get to excited could be the -pre- earnings rise, followed by an earnings/revenue mixed report. Marketeers are bipolar.
Amarin earnings expected tomorrow:
The consensus of the 4 analysts covering AMRN for 4th quarter 2018 is a per share value of USD -.07.
Mean Estimate: USD -0.066
High Estimate: USD -0.045
Low Estimate: USD -0.08
Revenues expected:
The consensus for revenue of the 3 analysts covering AMRN for 4th quarter 2018 is USD 73.9M.
Mean Estimate: USD 73.9M
High Estimate: USD 74.7M
Low Estimate: USD 72.7M
Actually if you dig further Vascepa 'EPA' modifies or fixes HDL particle's the quality, larger particle size, remember HDL-C also comes in different size types and can effect CVD. I would not worry so much about the raw measurement in itself, Like LDL-C better to measure particle size to assess risk as HDL-C is just another lipid. Don't take my word for it do some research.
Niacin and recent CVOT'S CETP inhibitors raised HDL-C by %100 and lowered LDL-C by around 50% yet failed CVOT primary outcomes. So a slight lowering may not have much meaning. Data from the Reduce-It trial it is obviously not a problem.
Nonsense shares are trading - PPS heading south now that buyout rumor served it's purpose.
Not comparing the two just the portfolio report! I thought you got that!
Explain LABU ETF appears to be mostly cash?
N40K, this is a portfolio report for BOTZ for example: Which shows
~%100 stocks.
Last Price Today’s Change Bid x Size Ask x Size Day’s Range Volume
$20.12 0.000 (0.00%) 19.51 x3,500 20.18 x1,000 -- - -- 0
NASDAQ Real Time Quote Last Trade as of 4:00 PM ET 2/25/19
Fund Report Prospectus Add to Watchlist Historical Quote
PORTFOLIO
Portfolio Analyzer »
Total Net Assets
$1.4 B
Yield
1.31%
SEC 30 Day Yield
0.82%
Number of Stock Holdings 36
Number of Bond Holdings 0
Portfolio Turnover
28.50%
as of 1/31/2019
Investment Style (%)
Short Interm Long
as of 1/31/2019
Market Capitalization (%)
as of 1/31/2019
ASSET ALLOCATION
By Percent Short Long Net
Cash 0 0 0
Stocks 0 99 99
Bonds 0 0 0
Other 0 0 0
Total 0 100 100
Foreign Stk 0 69 69
as of 1/31/2019
Like I said this report is in my Etrade account and it is LABU.
LABU DIREXION SHARES ETF TRUST DIREXION DAILY S&P BIOTECH BULL 3X SHARES.
As FFS mention I think this is designed for day traders.
and no enrollment required.
February 26, 2019 7:24 AM ET
NYSE Arca
LABU DIREXION SHARES ETF TRUST DIREXION DAILY S&P BIOTECH BULL 3X SHARES
Fund Family: Direxion Funds
Buy Sell
Snapshot
Charts
News
Options
Performance
Tax & Income
Risk & Ratings
Portfolio
Data quoted represents past performance. Past performance is not an indication of future results and investment returns and prices for exchange-traded funds will fluctuate. Your investment may be worth more or less than your original cost at redemption. Current performance may be lower or higher than the performance data quoted. Exchange-Traded Fund [ETF] shares cannot be redeemed directly from the ETF. Consequently, brokerage commissions will reduce the performance. For most recent quarter end performance, select the Performance view.
copy of screen for LABU.
Last Price Today’s Change Bid x Size Ask x Size Day’s Range Volume
$59.87 0.000 (0.00%) 59.03 x1,000 59.19 x100 -- - -- 4,510
NYSE Arca Real Time Quote Last Trade as of 8:00 PM ET 2/25/19
Fund Report Prospectus Add to Watchlist Historical Quote
PORTFOLIO
Portfolio Analyzer »
Total Net Assets
$626.9 M
Yield
0.42%
SEC 30 Day Yield
--
Number of Stock Holdings 0
Number of Bond Holdings 0
Portfolio Turnover
510.00%
as of 12/31/2018
Investment Style (%)
No Investment Style
as of 12/31/2018
Market Capitalization (%)
There is no market capitalization information for this fund.
ASSET ALLOCATION
By Percent Short Long Net
Cash 1 93 91
Stocks 3 11 8
Bonds 0 0 0
Other 0 0 0
Total 4 104 100
Foreign Stk 0 0 0
as of 12/31/2018
INTERNATIONAL EXPOSURE
That what I was thinking!